Group 1 - Hubei Changjiang No.1 Health Industry Investment Partnership has been established with a capital contribution of 3.401 billion RMB, primarily funded by Hubei Changjiang Industrial Investment Fund Co., Ltd. and Hubei Changjiang New Kinetic Energy Private Fund Management Co., Ltd. [1] - The fund aims to accelerate the development of the biopharmaceutical and health industry in Hubei, which is a key strategic pillar industry for the province, projected to reach a trillion-level scale [1][3]. - The establishment of the fund is expected to effectively promote the construction of biopharmaceutical industrial parks and project introductions [1]. Group 2 - Guangji Pharmaceutical, as the only provincial-level listed pharmaceutical company in Hubei, is a significant subsidiary of Changjiang Industrial Group, producing various vitamin products and serving as a major supplier of Vitamin B2 globally [2]. - The fund will provide strong capital support for Guangji Pharmaceutical in terms of industrial collaboration, project implementation, mergers, and development [2]. - The fund will also establish an expert committee to provide intellectual support for project advancement, enhancing the scientific and forward-looking aspects of industry development [2]. Group 3 - Changjiang Industrial Group was established in January 2022, with a registered capital of 33.6 billion RMB and total assets of 250.9 billion RMB, managing over 700 billion RMB in funds [3]. - The health industry in Hubei has surpassed 850 billion RMB in scale, accounting for 15% of the province's GDP, with expectations to exceed 950 billion RMB by 2025, reflecting a compound annual growth rate of 12%-15% [3]. - The "14th Five-Year Plan" for the development of the health industry in Hubei includes the establishment of a 10 billion RMB guiding fund to support sectors such as biopharmaceuticals and medical devices [3]. Group 4 - By the end of 2024, the number of high-tech enterprises in Hubei's health sector is expected to exceed 1,500, marking a 65% increase since 2020 [4]. - In the chemical pharmaceutical sector, companies like Renfu Pharmaceutical and Yuanda Pharmaceutical lead in specific markets such as anesthetics and eye drops [4]. - Wuhan Optics Valley Biomedicine City has over 400 biopharmaceutical companies, forming a regional cluster advantage in areas like genetic engineering and vaccine development [4].
长江一号健康产业投资基金成立 出资额超34亿元
Jing Ji Guan Cha Wang·2025-07-14 11:02